ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 793,400 shares, a drop of 52.2% from the February 28th total of 1,660,000 shares. Based on an average daily volume of 9,120,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.2% of the company’s stock are sold short.

Hedge Funds Weigh In On ProPhase Labs

A number of hedge funds have recently bought and sold shares of PRPH. HighTower Advisors LLC raised its holdings in ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after buying an additional 27,673 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ProPhase Labs by 9.2% during the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after acquiring an additional 13,590 shares in the last quarter. Sheets Smith Wealth Management purchased a new position in ProPhase Labs in the 4th quarter worth approximately $158,000. SVB Wealth LLC bought a new position in ProPhase Labs in the 4th quarter valued at approximately $36,000. Finally, Perritt Capital Management Inc boosted its stake in ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after purchasing an additional 107,068 shares during the last quarter. Institutional investors own 9.45% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on ProPhase Labs in a research note on Tuesday, February 25th. They issued a “sell” rating on the stock.

ProPhase Labs Stock Down 4.3 %

Shares of NASDAQ PRPH traded down $0.02 during trading on Friday, reaching $0.44. The company had a trading volume of 3,276,359 shares, compared to its average volume of 2,472,609. ProPhase Labs has a 12-month low of $0.22 and a 12-month high of $7.48. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The business’s 50-day moving average is $0.41 and its 200 day moving average is $1.08. The stock has a market cap of $10.50 million, a PE ratio of -0.35 and a beta of -0.53.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.